These findings highlight the potential of AFP analysis from CTCs and/or cfDNA as predictive tools in HCC management and suggest that serial monitoring of AFP expression changes in these biomarkers could be incorporated into clinical workflows to predict treatment efficacy at earlier stages. Here, AFP is linked to hepatocellular carcinoma.